MAGL is encoded by the MGLL gene and is expressed throughout the brain, liver, adipose tissue, and intestine. Its principal biochemical role is to hydrolyse 2-arachidonoylglycerol (2-AG) into arachidonic acid and glycerol, thereby terminating 2-AG signalling at CB1 and CB2 cannabinoid receptors. Because 2-AG acts as a retrograde messenger at synapses , travelling from postsynaptic to presynaptic neurons to modulate neurotransmitter release , MAGL activity is a direct regulator of the duration and magnitude of that signalling window. A separate enzyme, ABHD6, contributes to 2-AG hydrolysis at the postsynaptic membrane, but MAGL accounts for roughly 85% of 2-AG degradation in the brain according to substrate-competition studies published in Nature Chemical Biology (Blankman et al., 2007).
Structurally, MAGL is a 33 kDa cytosolic enzyme with a canonical serine–histidine–aspartate catalytic triad. It operates as a monomer, distinguishing it from many other lipases, and contains a hydrophobic lid domain that mediates transient association with cellular membranes where its lipid substrates reside. Pharmacological inhibition of MAGL , using tool compounds such as JZL184 in preclinical research; is a widely used strategy to elevate endogenous 2-AG levels in animal models, enabling researchers to study the downstream consequences of sustained CB receptor activation without exogenous cannabinoid administration.
Because arachidonic acid released by MAGL is a precursor to pro-inflammatory eicosanoids (prostaglandins, thromboxanes, leukotrienes), MAGL sits at a metabolic junction between endocannabinoid signalling and the arachidonic acid cascade. This dual substrate-product relationship has made it a subject of interest in inflammation biology. It should be noted explicitly that any hypothesis proposing MAGL deficiency or inhibition as a strategy to modulate neuroinflammatory or other pathological states remains at the preclinical hypothesis stage; no MAGL-targeting agent has received regulatory approval from the Therapeutic Goods Administration (TGA) or equivalent bodies for any clinical indication as of the date of this entry.
In the context of the Poisons Standard (Australia), no MAGL inhibitor is currently scheduled as a therapeutic substance, reflecting the absence of approved clinical formulations. Research-grade MAGL inhibitors are classified as laboratory reagents and are not approved therapeutic goods under the Therapeutic Goods Act 1989.
Sources: